Christian Angermayer

Psychedelics are becoming medically accepted again with clinical trials showing up to 80% responder rates for treatment-resistant depression, addiction, and anxiety disorders. The recent executive order from President Trump accelerates federal funding for research, and the drugs are used in a clinical setting with a therapist, ensuring safety and efficacy. The sector has strong growth potential and companies have patent protection and intellectual property.